Resource Logo
NLM AIDSLINE

Genotypic diversity of HIV-1 isolated from Mid-Atlantic United States.




 

Int Conf AIDS. 1992 Jul 19-24;8(3):43 (abstract no. PuA 6195). Unique

OBJECTIVES: Genotypic diversity among isolates of HIV-1 is widely appreciated. Isolates from certain areas of the world (e.g. Africa) show significant differences from other areas (e.g. North American or Europe). Despite this, very few isolates of HIV-1 from defined geographic areas of the U.S. have been sequenced. We have undertaken this study to better characterize and to determine relatedness of isolates obtained from a diverse population of patients residing in a medium prevalence area of the U.S. METHODS: HIV-1 was isolated from patient PBL's by co-cultivation with PHA- and IL-2 stimulated PBL target cells obtained from normal donors. PCR was used to amplify a 550 BP region of env encompassing V3. Both strands of the PCR products were sequenced directly by the dideoxynucleotide chain termination method. RESULTS: 20 isolates were obtained from individual patients and the PCR-amplified V3 region of env was sequenced. These isolates were obtained from patients of both sexes (adults and children) from both early and advanced disease, from patients from most risk groups, and from both untreated patients and those who had received antiretrovirals. Significant sequence diversity was appreciated in this population and detailed analysis is presented. CONCLUSIONS: Direct sequence analysis of PCR-amplified regions of env is a convenient approach to the study of genotypic diversity of HIV-1 and may be helpful in understanding the epidemiology of HIV infection in a community.

Acquired Immunodeficiency Syndrome/EPIDEMIOLOGY/*MICROBIOLOGY Adult Cells, Cultured Child Female *Genes, env Genotype Geography Human HIV-1/*GENETICS/*ISOLATION & PURIF Lymphocyte Transformation Lymphocytes/MICROBIOLOGY Male Mid-Atlantic Region Polymerase Chain Reaction Risk Factors *Variation (Genetics) ABSTRACT



 




Information in this article was accurate in December 30, 1992. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.